UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

381 SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A430-A430

2023

Volltextzugriff (PDF)

727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A822-A822

2023

Volltextzugriff (PDF)

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Immunity (Cambridge, Mass.), 1995-11, Vol.3 (5), p.541-547

1995

Volltextzugriff (PDF)

Alloplex Biotherapeutic’s SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer

Immuno Oncology Insights, 2023-04, Vol.4 (3), p.89-104

2023

Volltextzugriff (PDF)

B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center Formation

Immunity (Cambridge, Mass.), 1997-03, Vol.6 (3), p.303-313

1997

Volltextzugriff (PDF)

Abstract 1531: Development of PBMC derived tumor effector cells with potent pan-cancer cytolytic activity for autologous cellular immunotherapy

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1531-1531

2021

Volltextzugriff (PDF)

Abstract B63: Exploratory immune phenotyping of longitudinal blood samples from the first-in-human phase 1 clinical trial of a novel autologous cellular therapy in patients with metastatic solid tumors

Cancer immunology research, 2022-12, Vol.10 (12_Supplement), p.B63-B63

2022

Volltextzugriff (PDF)

Abstract 1772: A novel approach for autologous pan-cancer cellular immunotherapy reveals dramatic expansion of ab and gd TCR T cell clonotypes indicative of an antigen-driven response

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1772-1772

2021

Volltextzugriff (PDF)

Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7517-7517

2021

Volltextzugriff (PDF)

Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice

Science (American Association for the Advancement of Science), 1993-11, Vol.262 (5135), p.907-909

1993

Volltextzugriff (PDF)

Abstract 2753: Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2753-2753

2022

Volltextzugriff (PDF)

Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics

Scientific reports, 2019-03, Vol.9 (1), p.4847-4847, Article 4847

2019

Volltextzugriff (PDF)

632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A663-A663

2022

Volltextzugriff (PDF)

Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX-2 membrane glycoprotein

Mammalian genome, 1998-02, Vol.9 (2), p.114-118

1998

Volltextzugriff (PDF)

Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells

European journal of immunology, 2000-12, Vol.30 (12), p.3468-3477

2000

Volltextzugriff (PDF)

Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86

The Journal of immunology (1950), 1997-03, Vol.158 (6), p.2713-2722

1997

Volltextzugriff (PDF)

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production

The Journal of experimental medicine, 1993-12, Vol.178 (6), p.2185-2192

1993

Volltextzugriff (PDF)

Multiple Murine α1-Protease Inhibitor Genes Show Unusual Evolutionary Divergence

Proceedings of the National Academy of Sciences - PNAS, 1991-11, Vol.88 (21), p.9417-9421

1991

Volltextzugriff (PDF)

MRC OX-2 defines a novel T cell costimulatory pathway

The Journal of immunology (1950), 1997-05, Vol.158 (10), p.4548-4554

1997

Volltextzugriff (PDF)

Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation

European journal of immunology, 1995-01, Vol.25 (1), p.207-211

1995

Volltextzugriff (PDF)

The role of donor and recipient B7-1 (CD80) in allograft rejection

The Journal of immunology (1950), 1997-08, Vol.159 (3), p.1169-1173

1997

Volltextzugriff (PDF)

Functional consequences of dysregulated B7-1 (CD80) and B7-2 (CD86) expression in B or T lymphocytes of transgenic mice

The Journal of immunology (1950), 1997-12, Vol.159 (11), p.5336-5344

1997

Volltextzugriff (PDF)

Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5

The Journal of immunology (1950), 1994-12, Vol.153 (11), p.5038-5048

1994

Volltextzugriff (PDF)

Distinct roles for B7 costimulation in contact hypersensitivity and humoral immune responses to epicutaneous antigen

European journal of immunology, 1998-12, Vol.28 (12), p.4221-4227

1998

Volltextzugriff (PDF)

Reactive site polymorphism in the murine protease inhibitor gene family is delineated using a modification of the PCR reaction (PCR+1)

Nucleic acids research, 1990-09, Vol.18 (18), p.5481-5487

1990

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(38)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Animals
(17)
Life Sciences & Biomedicine
(17)
Mice
(15)
Immunology
(12)
Molecular Sequence Data
(11)
Amino Acid Sequence
(9)
B7-2 Antigen
(9)
Base Sequence
(8)
Humans
(8)
T-Lymphocytes - Immunology
(8)
B7-1 Antigen - Genetics
(7)
Biological And Medical Sciences
(7)
Antigens, Cd
(6)
Cell Line
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Mice, Inbred Balb C
(6)
Mice, Knockout
(5)
Polymerase Chain Reaction
(5)
Abatacept
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

381 SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function

727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Alloplex Biotherapeutic’s SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer

B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center Formation

Abstract 1531: Development of PBMC derived tumor effector cells with potent pan-cancer cytolytic activity for autologous cellular immunotherapy

Abstract B63: Exploratory immune phenotyping of longitudinal blood samples from the first-in-human phase 1 clinical trial of a novel autologous cellular therapy in patients with metastatic solid tumors

Abstract 1772: A novel approach for autologous pan-cancer cellular immunotherapy reveals dramatic expansion of ab and gd TCR T cell clonotypes indicative of an antigen-driven response

Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells

Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice

Abstract 2753: Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells

Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics

632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies

Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX-2 membrane glycoprotein

Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells

Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production

Multiple Murine α1-Protease Inhibitor Genes Show Unusual Evolutionary Divergence

MRC OX-2 defines a novel T cell costimulatory pathway

Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation

The role of donor and recipient B7-1 (CD80) in allograft rejection

Functional consequences of dysregulated B7-1 (CD80) and B7-2 (CD86) expression in B or T lymphocytes of transgenic mice

Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5

Distinct roles for B7 costimulation in contact hypersensitivity and humoral immune responses to epicutaneous antigen

Reactive site polymorphism in the murine protease inhibitor gene family is delineated using a modification of the PCR reaction (PCR+1)

Suchergebnisse filtern